Total Payments
$431,764
2024 Payments
$82,569
Companies
26
Transactions
310
Medicare Patients
329
Medicare Billing
$36,938
Payment Breakdown by Category
Consulting$207,757 (48.1%)
Other$116,069 (26.9%)
Research$60,864 (14.1%)
Travel$41,402 (9.6%)
Food & Beverage$5,672 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $207,757 | 75 | 48.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100,209 | 56 | 23.2% |
| Unspecified | $60,864 | 26 | 14.1% |
| Travel and Lodging | $41,402 | 59 | 9.6% |
| Honoraria | $15,860 | 4 | 3.7% |
| Food and Beverage | $5,672 | 90 | 1.3% |
Payments by Type
General
$370,900
284 transactions
Research
$60,864
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $106,391 | 75 | $0 (2024) |
| Janssen Biotech, Inc. | $72,719 | 64 | $0 (2024) |
| Celgene Corporation | $62,064 | 19 | $0 (2024) |
| ABBVIE INC. | $47,061 | 57 | $0 (2024) |
| Covidien LP | $24,977 | 11 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $19,379 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $17,110 | 21 | $0 (2024) |
| Takeda Pharmaceuticals International, Inc. | $14,756 | 6 | $0 (2018) |
| Janssen Global Services, LLC | $10,261 | 10 | $0 (2022) |
| Lilly USA, LLC | $8,400 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $82,569 | 57 | Janssen Biotech, Inc. ($32,792) |
| 2023 | $59,265 | 41 | ABBVIE INC. ($17,298) |
| 2022 | $29,473 | 22 | PFIZER INC. ($7,040) |
| 2021 | $47,615 | 19 | Celgene Corporation ($9,712) |
| 2020 | $63,133 | 25 | Covidien LP ($19,585) |
| 2019 | $58,174 | 62 | PFIZER INC. ($19,947) |
| 2018 | $54,086 | 50 | Takeda Pharmaceuticals International, Inc. ($14,756) |
| 2017 | $37,449 | 34 | PFIZER INC. ($25,912) |
All Payment Transactions
310 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6,194.10 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,654.61 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $119.59 | General |
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $95.60 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $575.00 | General |
| 11/13/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $521.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $695.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,865.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,865.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,128.00 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $87.11 | General |
| Category: Immunology | ||||||
| 10/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $35.15 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $1,218.05 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $146.19 | General |
| Category: Immunology | ||||||
| 10/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $967.40 | General |
| Category: Immunology | ||||||
| 10/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $346.85 | General |
| Category: Immunology | ||||||
| 10/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 10/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $1,050.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $142.48 | General |
| Category: IMMUNOLOGY | ||||||
| 08/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $10,200.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $799.85 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $443.36 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $171.72 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Induction Study #2 - A Phase 3, Multicenter, Rando | Celgene Corporation | $12,764 | 2 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $11,480 | 10 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) | Celgene Corporation | $9,128 | 1 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) | Celgene Corporation | $5,775 | 1 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) | Celgene Corporation | $5,273 | 1 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Celgene Corporation | $3,053 | 1 |
| Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $3,053 | 1 |
| RPC01-3202 - PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) | Celgene Corporation | $2,888 | 1 |
| To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | Celgene Corporation | $2,498 | 1 |
| PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) | Celgene Corporation | $1,400 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 119 | 133 | $69,869 | $13,502 |
| 2022 | 2 | 61 | 69 | $32,797 | $6,677 |
| 2021 | 3 | 97 | 108 | $49,931 | $11,189 |
| 2020 | 2 | 52 | 67 | $23,767 | $5,571 |
Total Patients
329
Total Services
377
Medicare Billing
$36,938
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 58 | 69 | $22,222 | $5,616 | 25.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 34 | 36 | $31,239 | $4,832 | 15.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $7,296 | $1,862 | 25.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 16 | $9,112 | $1,192 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 47 | $15,076 | $3,531 | 23.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 21 | 22 | $17,721 | $3,145 | 17.7% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 34 | 34 | $24,578 | $5,503 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 52 | $14,781 | $4,213 | 28.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 22 | 22 | $10,572 | $1,472 | 13.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 38 | 52 | $13,312 | $3,208 | 24.1% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 14 | 15 | $10,455 | $2,363 | 22.6% |
About Dr. Gil Melmed, M.D
Dr. Gil Melmed, M.D is a Gastroenterology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336102524.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gil Melmed, M.D has received a total of $431,764 in payments from pharmaceutical and medical device companies, with $82,569 received in 2024. These payments were reported across 310 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($207,757).
As a Medicare-enrolled provider, Melmed has provided services to 329 Medicare beneficiaries, totaling 377 services with total Medicare billing of $36,938. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Los Angeles, CA
- Active Since 04/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1336102524
Products in Payments
- XELJANZ (Drug) $80,296
- STELARA (Biological) $35,455
- TREMFYA (Drug) $34,126
- ZEPOSIA (Drug) $27,832
- Entyvio (Biological) $26,084
- RINVOQ (Biological) $23,218
- SKYRIZI (Biological) $19,957
- VELSIPITY (Drug) $14,023
- Otezla (Drug) $9,471
- SPEVIGO (Drug) $8,849
- Tremfya (Drug) $8,746
- RPC-1063 (Drug) $7,175
- SIMPONI (Biological) $6,953
- SHINGRIX (Biological) $6,436
- OMVOH (Drug) $6,000
- Non-Covered Product (Drug) $5,400
- Barrx (Device) $4,662
- Symproic (Drug) $3,443
- Pomalyst (Drug) $3,053
- Ozanimod (Drug) $2,888
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Los Angeles
Bennett Roth, Md, MD
Gastroenterology — Payments: $4.3M
Gastroenterology $4.3M
Dr. Mark Pimentel, M.d, M.D
Gastroenterology — Payments: $368,269
Gastroenterology $368,269
Dr. Venkataraman Muthusamy, Md, MD
Gastroenterology — Payments: $344,206
Gastroenterology $344,206
Dr. Joseph Pisegna, Md, MD
Gastroenterology — Payments: $257,321
Gastroenterology $257,321
Brennan Spiegel, Md, MD
Gastroenterology — Payments: $235,801
Gastroenterology $235,801
Dr. Adarsh Thaker, M.d, M.D
Gastroenterology — Payments: $181,859
Gastroenterology $181,859